Studies
The papers I'm actually reading. Recent research on every compound here, newest first. Read the abstracts before you trust anyone's marketing.
The Power of Two: Harnessing Dual Glucagon and Incretin Signaling for Treatment of Obesity and Metabolic Dysfunction-Associated Steatohepatitis-A Narrative Review with a Translational Focus
Retatrutide in adults with obesity and type 2 diabetes: what have we learned from TRIUMPH-2?
Preconception incretin therapy reduces pregnancy and cardiometabolic outcomes in polycystic ovary syndrome
Tirzepatide-induced pneumatosis intestinalis: a rare but clinically significant gastrointestinal adverse effect
A GLP-1/apelin dual receptor agonist shows neuroprotective effects in the MPTP mouse model of Parkinson's disease
Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain
Cardiovascular Risk in SELECT-Eligible MI Patients With Overweight or Obesity: The Western Denmark Heart Registry
GLP-1 Receptor Biology and the Therapeutic Role of Incretin-Based Agonists in Metabolic Diseases
Combined empagliflozin and liraglutide therapy protects against tacrolimus-induced pancreatic and renal injury associated with oxidative stress reduction
Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide
Severe Euglycemic Diabetic Ketoacidosis After Semaglutide-Associated Poor Intake Despite Empagliflozin Discontinuation: A Case Report
Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3)
Chicken cathelicidin-3 protected mice from avian pathogenic Escherichia coli infection mediated by triggering chemokine CCL3 pathway
Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties
Current review of glucagon-like peptide 1 receptor agonists and risk of nonarteritic anterior ischemic optic neuropathy
Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents
Nephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease
Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes
Cardiomyocyte-specific expression of HIF-1α mediates the cardioprotective effects of growth hormone-releasing hormone
Growth hormone - releasing hormone antagonists protect endothelial corneal cells against lipopolysaccharides-induced inflammation
Mitochondrial Peptide SHLP2 Limits Poly(I: C)-Induced Alveolar Epithelial Injury by Modulating Redox, Apoptotic, Inflammatory, and Inflammasome Responses
Elamipretide Rejuvenates Oocyte Quality and Restores Female Fertility During Reproductive Aging
Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review
New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus